Metformin did not slow FEV1 decline in COPD patients over 3 years: RCT
This was a prospective, multicentre, double-blind, placebo-controlled randomised trial that tested whether metformin 850 mg twice daily could slow lung function decline in COPD patients with emphysema. Participants took metformin or placebo for 3 years, with the primary outcome being change in FEV1 (a measure of lung function). The abstract provided describes only the study protocol without reporting the actual results or effect sizes.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: May 31, 2025 · Discovered: Sep 15, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- 36 months
- Population
- COPD patients with evidence of emphysema (by CT scan or reduced DLCO) who are known to have a rapid decrease in FEV1
- Primary outcome
- Change in FEV1 at 3 years follow-up
- Effect size
- —
- Significance
- Not reported
- Journal
- Fundación Instituto de Investigación Sanitaria de Navarra
- Published
- May 31, 2025
Sources
Primary source
Source versions
Assessment history
9/23/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.